Cell therapy and humoral alloimmunity post-transplantation: a review of immunoregulatory mechanisms, preclinical studies, and clinical outcomes of cell therapy for transplantation

Cellular therapies are a novel therapeutic approach that may safely and effectively suppress acute rejection, minimize the amount of maintenance immunosuppressive drugs needed, and preserve protective immunity against infections. However, less is known about the efficacy of cell therapies for suppression of humoral alloimmunity after transplantation. We review the pre-clinical and clinical solid organ transplant experience with cell therapies that have progressed to clinical trials including CD4 + T regulatory cells (Treg), mesenchymal stem cells (MSC), hematopoietic stem cells (HSC), and regulatory dendritic cells (DCreg) as well as experimental cell therapies in development with antibody-suppressor CXCR5 + CD8 + T cells (CD8 + T Ab-supp cells). While cell therapies have been well tolerated and demonstrate efficacy for immunosuppression minimization or withdrawal, they have not prevented the development of de novo donor specific antibody ( dn DSA) which is known to be associated with reduced long-term allograft survival. The yield of ex vivo expansion protocols, in vivo persistence of cells infused (survival, proliferation, and trafficking), compatibility with conventional immunosuppressive agents, and adverse effects are also examined. This review uniquely analyzes the outcome of cell therapies in transplantation from the perspective of efficacy not only for study endpoints but for suppression of humoral alloimmunity, the compatibility with common maintenance immunosuppressive agents, and opportunities to optimize future cell therapy trial design and data collection.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-16
DOI
https://doi.org/10.3389/fimmu.2026.1946651
Primary Topic
T-cell and B-cell Immunology
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cell therapy and humoral alloimmunity post-transplantation: a review of immunoregulatory mechanisms, preclinical studies, and clinical outcomes of cell therapy for transplantation

Ginny L. Bumgardner, Nadia Rajab, Jason M. Zimmerer, Colleen Booth et al.
Frontiers in Immunology
T-cell and B-cell Immunology
article

Cell therapy and humoral alloimmunity post-transplantation: a review of immunoregulatory mechanisms, preclinical studies, and clinical outcomes of cell therapy for transplantation

Ginny L. Bumgardner, Nadia Rajab, Jason M. Zimmerer, Colleen Booth, Hope Uwase, Kavya Koneru, Hatem Aldhahi, Shane R. E. Walters
article en

Abstract

Cellular therapies are a novel therapeutic approach that may safely and effectively suppress acute rejection, minimize the amount of maintenance immunosuppressive drugs needed, and preserve protective immunity against infections. However, less is known about the efficacy of cell therapies for suppression of humoral alloimmunity after transplantation. We review the pre-clinical and clinical solid organ transplant experience with cell therapies that have progressed to clinical trials including CD4 + T regulatory cells (Treg), mesenchymal stem cells (MSC), hematopoietic stem cells (HSC), and regulatory dendritic cells (DCreg) as well as experimental cell therapies in development with antibody-suppressor CXCR5 + CD8 + T cells (CD8 + T Ab-supp cells). While cell therapies have been well tolerated and demonstrate efficacy for immunosuppression minimization or withdrawal, they have not prevented the development of de novo donor specific antibody ( dn DSA) which is known to be associated with reduced long-term allograft survival. The yield of ex vivo expansion protocols, in vivo persistence of cells infused (survival, proliferation, and trafficking), compatibility with conventional immunosuppressive agents, and adverse effects are also examined. This review uniquely analyzes the outcome of cell therapies in transplantation from the perspective of efficacy not only for study endpoints but for suppression of humoral alloimmunity, the compatibility with common maintenance immunosuppressive agents, and opportunities to optimize future cell therapy trial design and data collection.

Frontiers in ImmunologyVol. 17
The Ohio State University Wexner Medical Center (US), The Ohio State University (US)
Ohio State University, National Institutes of Health, National Institute of Allergy and Infectious Diseases
Good health and well-being
T-cell and B-cell Immunology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon